Sutro Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Sutro Biopharma

30/03/2023 23:04

* Sutro Biopharma Inc  STRO.OQ  reported a quarterly
adjusted loss
of 68 cents​​ per share for the quarter ended in December. The
mean expectation of eight analysts for the quarter was for a
loss of 62 cents per share.
    * Revenue fell 19% to $8.63 million from a year ago;
analysts
expected $14.48 million. 
    * Sutro Biopharma Inc's reported EPS for the quarter was a
loss
of 68 cents​.
    * The mean earnings estimate of analysts had risen by
about 5% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Sutro Biopharma Inc shares had fallen by 41.0% this
quarter.
    * The company reported a quarterly loss of $34.59 million.
    * Wall Street's median 12-month price target for Sutro
Biopharma
Inc is $20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 10:04 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.62          -0.68          Missed
 Sep. 30 2022      -0.74          -0.37          Beat
 Jun. 30 2022      -0.46          -0.55          Missed
 Mar. 31 2022      -0.76          -0.84          Missed